all report title image
  • Published On : Sep 2022
  • Code : CMI5247
  • Industry : Biotechnology
  • Pages : 249
  • Formats :

Research antibodies act as vital tools in laboratory techniques such as western blotting etc. that are conducted for research purposes. Due to their high specificity and sensitivity, antibodies and associated reagents make an important tool that aids in the detection of molecules and its analysis, which allows researchers to draw conclusions related to drug target, disease occurrence, and immune system pathways. Research antibodies are essential detecting techniques used by scientists. When attempting to understand why a cell function has gone wrong, antibodies can be used to mark and identify specific proteins that are present in the diseased cell at a specific stage of the disease life cycle.

Global Research Antibodies Market - Impact of the Coronavirus (COVID-19) Pandemic

Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19 as pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 610 million cases and 6.51 million deaths due to coronavirus (COVID-19) were reported till September 22, 2022, across the globe.

Impact of COVID-19 on Demand and Supply of Research Antibodies

The COVID-19 pandemic and lockdown in various countries across the globe has impacted the financial status of businesses across all sectors including private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. The COVID-19 pandemic has affected the economy of various regions across the globe in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets. Several countries such as Thailand, Indonesia, and Singapore are facing problems with regards to transportation and distribution of healthcare products.

However, Coronavirus (COVID-19) pandemic is expected to positively impact growth of the global research antibodies market during the forecast period. For instance, in February, 2022, U.S. Food and Drug Administration (FDA), granted an emergency use authorization (EUA) of novel monoclonal antibody against the omicron variant for the treatment of COVID-19. EUA was authorized for mild to moderate COVID-19 in adults and children (12 years of age and older) who weigh at least 40 kilograms (88 pounds) and patients who have a positive COVID-19 test.

Global research antibodies market is estimated to be valued at US$ 3,574.6 Mn in 2022, and is expected to exhibit a CAGR 5.9% over the forecast period (2022-2030).

Figure 1: Global Research Antibodies Market Share (%) Analysis, By Product Type, 2022

Research Antibodies  | Coherent Market Insights

Increasing research and development activities related to research antibodies are expected to drive the growth of market over the forecast period.

Increasing research and development activities related to research antibodies are expected to fuel growth of the global research antibodies market over the forecast period. For instance, according to a research article published in the journal eLife, non-profit, open access, scientific journal for the biomedical and life sciences, in March 2022, the study was conducted by researchers at the University of Washington, the Max Planck Institute for Dynamics and Self-Organization, and the University of Cologne on broadly neutralizing antibodies, or bNAbs (Broadly Neutralizing Antibodies) and it was observed that bNAbs could be used to treat HIV (Human Immunodeficiency Virus) while reducing the risk of the spreading virus. The study demonstrates that computational methods for selecting combinations of bNAbs based on viral genetics will help prevent viral escape, increasing the efficacy of HIV treatment.

Increasing product launches and approvals by market players are expected to drive growth of the global research antibodies market over forecast period.

Market players are engaged in product approvals, which is expected to boost the global research antibodies market growth over the forecast period. For instance, on January 21, 2020, Horizon Therapeutics plc, a biopharmaceutical company focused on researching, developing, and commercializing medicines, received the U.S. FDA (Food and Drug Administration) approval for the Tepezza (TM) (teprotumumab-trbw), therapeutic monoclonal antibody for the Treatment of Thyroid Eye Disease (TED). TED is a severe, progressive, and eyesight-threatening uncommon autoimmune condition that is accompanied by proptosis (eye bulging), diplopia (double vision), blurred vision, pain, inflammation, and facial disfigurement. Tepezza is the first and only medication for TED to get the U.S. FDA (Food and Drug Administration) approval.

CMI table icon

Research Antibodies Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 3,574.6 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 5.9% 2030 Value Projection: US$ 5,637.8 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Product Type: Primary Antibodies, Secondary Antibodies, Reagents, Consumables
  • By Form: Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Antibodies
  • By Source: Mouse, Rabbit, Goat, Others (Guinea Pigs, Rat etc.)
  • By Application: Western Blotting, ELISA, Flow Cytometry, Immunocytochemistry (ICC)/ Immunofluorescence (IF), Immunohistochemistry (IHC), Others (Immunoprecipitation, Multiplex Immunosorbent Assay and etc.)
  • By End User: Academic & Research Institutes, Contract Research Organizations, Pharmaceutical & Biotechnology Companies
Companies covered:

Thermo Fisher Scientific Inc, Bio-rad Laboratories, Lonza Group, Merck Millipore, Cell Signalling Technology Inc., F.Hoffmann La Roche Ltd., Novartis AG, Takeda Pharmaceutical Company, Agilent Technologies, Danaher Corporation, BioLegend Inc., Illumina, Phoenix Pharmaceuticals, Abcam plc

Growth Drivers:
  • Increasing research and development activities related to research antibodies
  • Increase in number of product approvals
  • Increasing cases of lung cancers 
Restraints & Challenges:
  • Challenges associated with storage conditions of antibodies

Restraint- Global Research Antibodies Market

Challenges associated with storage conditions of antibodies is expected to hamper the growth of global research antibodies market over forecast period, challenges include –

  • Monoclonal antibodies should be stored at -20°C in 50% glycerol
  • Polyclonal antibodies should be stored at -20°C up to -80°C
  • The major problem encountered during storage is contamination with bacteria or fungi 
  • When stored for a long period of time, some antibody solutions may produce an insoluble lipid component 
  • Undiluted antibodies should always be aliquoted prior to storage at -20 °C to minimize repeated freeze/thaw cycles that can denature antibody

Global Research Antibodies Market – Regional Analysis

On the basis of region, the global research antibodies market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to be the most lucrative region in the global research antibodies market, owing to increasing cases of lung cancer in the U.S. For instance, according to Centers of Disease Control and Prevention, in 2019, 221,097 new cases of lung and bronchus cancer were reported, and 139,601 people died of this cancer in the U.S.

Europe is expected to witness significant growth in the forecast period, owing to increasing approvals for monoclonal antibodies for the treatment of diseases. For instance, in December 2021, Vir Biotechnology, Inc., U.S.-based Biotechnology Company and GlaxoSmithKline plc. a British multinational pharmaceutical and biotechnology company announced that the European Commission (EC) approved Xevudy (sotrovimab) for commercialization for the early treatment of COVID-19. Sotrovimab is now approved in the European Union (EU) for the treatment of adults and adolescents with COVID-19 who do not require supplemental oxygen and are at elevated risk of advancing to severe COVID-19 (aged 12 years and above and weighing at least 40kg).

Figure 2: Global Research Antibodies Market Value (US$ Mn), by Region, 2022

Research Antibodies  | Coherent Market Insights

Global Research Antibodies Market – Competitive Landscape

Major players operating in the global research antibodies market include Thermo Fisher Scientific Inc, Bio-rad Laboratories, Lonza Group, Merck Millipore, Cell Signalling Technology Inc., F.Hoffmann La Roche Ltd., Novartis AG, Takeda Pharmaceutical Company, Agilent Technologies, Danaher Corporation, BioLegend Inc., Illumina and Phoenix Pharmaceuticals.

The small proteins known as antibodies, which are an essential component of immune system's reaction to diseases, are helpful in biomedical research. For decades, researchers have been developing antibodies to fight and understand viruses like Covid-19 and many common infectious disorders. The majority of antibodies used in research are referred to as "animal-derived" and are obtained from animals. A small quantity of the desired foreign antigen is injected into an animal. This triggers the immune system to generate antibodies in defense. These are then collected for use in research, either from the spleen or the blood.

Market Dynamics

Increasing collaborations and partnerships in market players is expected to witness significant growth in forecast period. For instance, in March 2022, Sanofi, a French multinational pharmaceutical and healthcare company and Seagen Inc., an American biotechnology company announced an exclusive collaboration agreement to design, develop, and market antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will make use of the exclusive monoclonal antibody (mAb) technology from Sanofi and the exclusive ADC technology from Seagen. Sanofi is now working on an ADC, which is an antibody designed to carry powerful anti-cancer medications to tumor cells expressing a certain protein.

Increasing product launches by market players are expected to drive growth of the global research antibodies market over the forecast period. For instance, in April 2019, ImmunoPrecise, a full-service, therapeutic antibody discovery company launched DeepDisplay, Antibody Discovery Platform with an unknown U.S. based Pharma Company. In contrast to conventional technologies, DeepDisplay uses a transgenic animal immunization combined with phage display antibody selection to deliver the most therapeutically-relevant antibodies in the shortest amount of time with the highest chances of success.

Increasing product approvals are expected to drive growth of market over the forecast period. For instance, in April 2021, Gilead Sciences Inc., an American biopharmaceutical company announced that Trodelvy (sacituzumab govitecan-hziy), for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer, has received full approval from the U.S. Food and Drug Administration (FDA). Trodelvy (sacituzumab govitecan-hziy) is an antibody–drug conjugate that combines a humanized monoclonal antibody.

Key features of the study:

  • This report provides an in-depth analysis of the global research antibodies market, market size (US$ Million), and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains an attractive investment proposition matrix for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global research antibodies market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
  • Key companies covered as a part of this study include Thermo Fisher Scientific Inc, Bio-rad Laboratories, Lonza Group, Merck Millipore, Cell Signalling Technology Inc., F.Hoffmann La Roche Ltd., Novartis AG, Takeda Pharmaceutical Company, Agilent Technologies, Danaher Corporation, BioLegend Inc., Illumina, Phoenix Pharmaceuticals and Abcam plc.
  • Insights from this report would allow marketers and the management authorities of the companies to make an informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics.
  • The global research antibodies market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global research antibodies market

Detailed Segmentation:

  • Global Research Antibodies Market, By Product Type:
    • Primary Antibodies
    • Secondary Antibodies
    • Reagents
    • Consumables
  • Global Research Antibodies Market, By Form:
    • Monoclonal Antibodies
    • Polyclonal Antibodies
    • Recombinant Antibodies
  • Global Research Antibodies Market, By Source:
    • Mouse
    • Rabbit
    • Goat
    • Others (Guinea Pigs, Rat etc.)
  • Global Research Antibodies Market, By Application:
    • Western Blotting
    • ELISA
    • Flow Cytometry
    • Immunocytochemistry (ICC)/ Immunofluorescence (IF)
    • Immunohistochemistry (IHC)
    • Others (Immunoprecipitation, Multiplex Immunosorbent Assay and etc.)
  • Global Research Antibodies Market, By End User:
    • Academic & Research Institutes
    • Contract Research Organizations
    • Pharmaceutical & Biotechnology Companies
  • Global Research Antibodies Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Thermo Fisher Scientific Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • Bio-rad Laboratories
    • Lonza Group
    • Merck Millipore
    • Cell Signalling Technology Inc.
    • F.Hoffmann La Roche Ltd.
    • Novartis AG
    • Takeda Pharmaceutical Company
    • Agilent Technologies
    • Danaher Corporation
    • BioLegend Inc.
    • Illumina
    • Phoenix Pharmaceuticals
    • Abcam plc.

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

Global research antibodies market is expected to exhibit a CAGR of 5.9% during the forecast period (2022-2030).
The market is estimated to be valued at US$ 3,574.6 Mn in 2022.
Thermo Fisher Scientific Inc., Bio-rad Laboratories, Lonza Group, Merck Millipore, Cell Signalling Technology Inc., F.Hoffmann La Roche Ltd., Novartis AG, Takeda Pharmaceutical Company, Agilent Technologies, Danaher Corporation, BioLegend Inc., Illumina, Phoenix Pharmaceuticals are the prominent players operating in the market across the globe.
The market is expected to be valued at US$ 5,637.8 Mn in 2030.
North America is the prominent region in the market.
Increasing research and development activities related to research antibodies, increase in product approvals and increasing cases of lung cancers are some of the driving factors, which are expected to drive growth of the market.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo